PacBio shares fell 4.7% after earnings, as higher revenue and instrument placements were tempered by a still-modest consumables increase and management’s acknowledgement of uneven capital purchasing, particularly in the Americas. The SPRQ-Nx transition is progressing, but customers are still validating workflows and establishing reorder patterns, leaving the timing of higher utilization uncertain.
Shares dropped 14.5% following earnings as the market reacted to weaker-than-expected instrument revenue, particularly from the Vega system, driven by continued academic funding pressure and regional challenges, signaling concerns about deceleration and margin pressure.